ENGOT-ov50/INNOVATE 3 (A González)
Pivotal, of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC).
ENGOT-ov34/GEICO 65-O/AGO-OVAR 2.29 (A Redondo)
Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer – a randomized Phase III trial.
SOV09 / ENGOT-ov53 (I Romero)
A phase III, multicentre, randomized, double-blind, placebo-controlled trial of DCVAC/OvCa added to standard of care induction and maintenance therapy in patients with relapsed platinum-sensitive ovarian, fallopian tube, and primary peritoneal carcinoma.
GEICO 87-R/RUCAPARIB (A Yubero)
Analysis of the experience with Rucaparib in Rucaparib access program , RAP, in Spain.
GEICO 88-R/ NIRAPARIB (J Cueva)
A Retrospective multicenter and observational study of Niraparib in patiens with platinum sensitive recurrent ovarian cancer who have received at least one dose of Niraparib within the EAP in Spain.
ENGOT-ov41/GEICO 69-O/ANITA (A González)
A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months
GEICO 60-O/BORNEO (I Romero)
Incidence of Somatic and Germline BRCA Mutations in a Spanish Large Clinic-Based Cohort of Patients with non-Mucinous Epithelial Ovarian Cancer with Cross-Laboratory Validation of Somatic Technique
ENGOT-OV44/GEICO 77-O/FIRST (A Redondo)
Phase 3 of Standard Platinum Based Therapy versus Platinum Therapy and TSR-042 Followed by Niraparib and TSR-042 Maintenance Therapy in Patients with Stage III or IV Cancer of the Ovary, Fallopian Tube, or Peritoneum
ENGOT-ov46/GEICO 76-O/DUO-O (MJ Rubio)
Phase III of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients
ENGOT-ov45/GEICO 74-O/ATHENA (A Oaknin)
A Phase 3 Study of Rucaparib in combination with Nivolumab versus Placebo as Switch Maintenance Following Response to Front-Line Platinum-Based Chemotherapy in Patients with High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
ENGOT-ov43/GEICO 80-O (A González)
A Phase 3 of Pembrolizumab Plus Chemotherapy Followed by Olaparib Maintenance and Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone for the First-Line Treatment of Non-Mutated BRCA Advanced Epithelial Ovarian Cancer
ENGOT-ov38/GEICO 62-O/OReO (A Redondo)
A Phase IIIb of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated with a PARPi and Responding to Repeat Platinum Chemotherapy
GEICO 55-O/ROLANDO (A Pérez Fidalgo)
Phase II trial of olaparib + Pegylated liposomal doxorubicin (PLD) for resistant ovarian cancer patients.